Steven Cohen Ventyx Biosciences, Inc. Transaction History

Point72 Asset Management, L.P.

$40.1 Billion
Q1 2025

A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Ventyx Biosciences, Inc. stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 4,234,804 shares of VTYX stock, worth $5.12 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

4,234,804

Previous 1,782,007 137.64%

Holding current value

$5.12 Million

Previous $3.9 Million 24.81%

% of portfolio

0.01%

Previous 0.01%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	BUY	$1.15 - $2.52 $2.82 Million - $6.18 Million	2,452,797 Added 137.64%	4,234,804 $4.87 Million
Q4 2024 Feb 14, 2025	BUY	$1.72 - $3.12 $3.07 Million - $5.56 Million	1,782,007 New	1,782,007 $3.9 Million
Q1 2024 May 15, 2024	BUY	$1.9 - $10.13 $4.81 Million - $25.6 Million	2,531,002 New	2,531,002 $13.9 Million
Q3 2023 Nov 14, 2023	BUY	$29.8 - $40.3 $14.9 Million - $20.1 Million	499,493 Added 62.51%	1,298,493 $45.1 Million
Q2 2023 Aug 14, 2023	SELL	$28.53 - $39.55 $7.71 Million - $10.7 Million	-270,400 Reduced 25.29%	799,000 $26.2 Million
Q1 2023 May 15, 2023	BUY	$29.51 - $46.65 $20.4 Million - $32.2 Million	690,100 Added 181.94%	1,069,400 $35.8 Million
Q4 2022 Feb 14, 2023	BUY	$24.16 - $36.38 $9.16 Million - $13.8 Million	379,300 New	379,300 $12.4 Million
Q2 2022 Aug 15, 2022	SELL	$11.95 - $18.75 $237,805 - $373,125	-19,900 Reduced 8.79%	206,400 $2.52 Million
Q1 2022 May 16, 2022	BUY	$10.0 - $19.98 $2.26 Million - $4.52 Million	226,300 New	226,300 $3.07 Million

Others Institutions Holding VTYX

# of Institutions

129

Shares Held

44.8M

Call Options Held

35.2K

Put Options Held

40.6K

View Full List

About Ventyx Biosciences, Inc.

Ticker VTYX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,527,200
Market Cap $68.4M
Description
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis...

More about VTYX

Track Steven Cohen's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.

Account